personalized neoantigen peptide vaccine + poly-ICLC + checkpoint inhibitors

This is a combination immunotherapy regimen consisting of three components: - **Personalized neoantigen peptide vaccine**: A custom-made cancer vaccine created for each patient by sequencing their tumor and identifying unique mutations (neoantigens). Synthetic peptides corresponding to these neoantigens are manufactured and administered to stimulate the patient's immune system to recognize and attack cancer cells. These vaccines are typically composed of multiple long peptides (15–31 amino acids) designed to cover both MHC class I and II epitopes, enhancing T cell responses against tumor-specific mutations[2][3][4][5]. - **Poly-ICLC**: A synthetic double-stranded RNA complex that acts as an adjuvant by mimicking viral infection. It activates innate immunity through Toll-like receptor 3 (TLR3) and other cytoplasmic sensors, leading to dendritic cell activation, type I interferon production, Th1 polarization, and enhanced antigen presentation[6]. Poly-ICLC is used in cancer vaccines to boost immune responses. - **Checkpoint inhibitors**: Monoclonal antibodies targeting immune checkpoints such as PD-1 or PD-L1 (e.g., pembrolizumab), which release the brakes on T cells, allowing them to mount a stronger anti-tumor response. Checkpoint inhibitors have transformed cancer therapy but often benefit only a subset of patients; combining them with personalized vaccines aims to increase efficacy[5][7]. The rationale for this combination is that the personalized vaccine primes the immune system against tumor-specific antigens; poly-ICLC enhances innate immunity and antigen presentation; checkpoint inhibitors prevent suppression of activated T cells within the tumor microenvironment. This approach is being investigated in early-phase clinical trials for advanced solid tumors including melanoma, breast cancer, colon cancer, non-small cell lung cancer, urothelial carcinoma, head & neck cancers, among others[2][3][5][7].